Medincell Shares Drop 2.91% in Late Afternoon Despite Stifel's Support

Stifel Adjusts Price Target for Medincell

This Thursday, Stifel adjusted its price target on Medincell, lowering it from 37 to 33 euros, while reaffirming its 'accumulate' recommendation. This target suggests a potential appreciation of 41.5% from the current stock level. This revision follows another recent analyst action: Oddo BHF raised its target from 27 to 34 euros in mid-January, also maintaining an 'outperform' rating. Both institutions thus display broadly similar stances. The difference between the two targets reflects distinct methodologies in the face of uncertainties surrounding the regulatory and commercial timeline of the Montpellier-based pharmaceutical laboratory.

Medincell, through Partner Teva Pharmaceuticals, Announces Key Regulatory Milestone

The company announced via its partner Teva Pharmaceuticals that the filing of a European authorization request for olanzapine LAI is expected in the second quarter of 2026. This timeline marks a crucial step in the commercial rollout of this long-acting injectable formulation intended for the treatment of schizophrenia. The now specified schedule targets the main European markets and is part of the laboratory's geographical expansion strategy. This announcement comes at a time when the stock is undergoing a challenging period, trading below its 50-day moving average (26.85 euros) and displaying an RSI indicator of 45, indicating a fragile balance between selling pressure and attempts at stabilization. The increased visibility on the regulatory process could reassure some investors about the growth prospects of the company's product portfolio.